Summary for 29MM
| Entry DOI | 10.2210/pdb29mm/pdb |
| Descriptor | Tyrosine-protein phosphatase non-receptor type 11, (4S)-1'-[5-(3-chloranyl-2-pyrazol-1-yl-pyridin-4-yl)sulfanylpyrazin-2-yl]spiro[4,6-dihydropyrrolo[1,2-b]pyrazole-5,4'-piperidine]-4-amine, SULFATE ION, ... (6 entities in total) |
| Functional Keywords | inhibitor, hydrolase |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 2 |
| Total formula weight | 121774.14 |
| Authors | Petrocchi, A.,Ciammaichella, A. (deposition date: 2026-03-23, release date: 2026-08-12, Last modification date: 2026-08-26) |
| Primary citation | Ciammaichella, A.,Puca, F.,Fabbrini, D.,Randazzo, P.,Rossetti, I.,Sferrazza, A.,Ferrigno, F.,Grillo, A.,Torrente, E.,Iaccarino, C.,Amaudrut, J.,Cellucci, A.,Di Marco, A.,Palombo, S.,Esposito, S.,Bisbocci, M.,Orsale, M.V.,Nibbio, M.,Missineo, A.,Scalabri, F.,Fodale, V.,Pucci, V.,Alli, C.,Di Fabio, R.,Montalbetti, C.,Carugo, A.,Toniatti, C.,Petrocchi, A. Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers. J.Med.Chem., 69:18898-18914, 2026 Cited by PubMed Abstract: SHP2 (Src homology 2 (SH2)-containing protein tyrosine phosphatase 2) is a tyrosine phosphatase that plays a critical role in numerous physiological and pathological cellular processes, including cell proliferation, survival, and migration through the regulation of multiple signaling pathways, such as RAS-RAF-mitogen-activated protein kinase, phosphatidylinositol 3-kinase (PI3K)-AKT, Janus tyrosine kinase (JAK), and signal transducer and activator of transcription pathways (STAT) in response to cytokines and growth factors. Through extensive structure-based optimization, we identified I-0436650, a preclinical candidate with an excellent pharmacological profile. I-0436650 is a low nanomolar allosteric inhibitor of human wild-type (wt) SHP2 and strongly inhibits ERK phosphorylation in cells. It exhibits antiproliferative activity in EGFR- and RAS-dependent cell lines, suppresses tumor growth as a single agent in xenograft models, and delays tumor relapse when combined with inhibitors of the same pathway, demonstrating the potential of vertical inhibition strategies. PubMed: 42593923DOI: 10.1021/acs.jmedchem.6c01182 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.197 Å) |
Structure validation
Download full validation report






